info:eu-repo/semantics/article
Cabergoline treatment in cats with diabetes mellitus and hypersomatotropism
Fecha
2022-02Registro en:
Miceli, Diego Daniel; García, Jorge D; Pompili, Gustavo A; Rey Amunategui, Juan P; Ferraris, Sergio; et al.; Cabergoline treatment in cats with diabetes mellitus and hypersomatotropism; Elsevier; Journal of Feline Medicine and Surgery; 144; 2-2022; 1-7
1098-612X
CONICET Digital
CONICET
Autor
Miceli, Diego Daniel
García, Jorge D
Pompili, Gustavo A
Rey Amunategui, Juan P
Ferraris, Sergio
Pignataro, Omar Pedro
Guitelman, Mirtha Adriana
Resumen
The aim of this study was to evaluate the safety and efficacy of cabergoline to control hypersomatotropism (HST) and diabetes mellitus (DM) in cats.
This was a prospective cohort study. Twenty-three cats with HST and concurrent DM were enrolled. Cats received a dose of 10 μg/kg cabergoline q48h PO for 6 months. Serum insulin-like growth factor 1 (IGF-1) and fructosamine concentrations, insulin dose and Insulin Resistance Index (IRI) were measured at the time of diagnosis of HST and at the start of cabergoline treatment (t0), and 3 months (t1) and 6 months (t2) during cabergoline treatment.